Showing 5501-5510 of 5956 results for "".
- Kodiak Sciences Announces Positive Interim Data from Phase 1b Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-positive-interim-data-from-phase-1b-study-of-ksi-301-a-novel-anti-vegf-antibody-biopolymer-conjugate-for-treatment-of-retinal-diseases/2476775/Kodiak Sciences announced positive interim results from the ongoing phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naïve wet age-related macular degeneration (AMD), diabetic mac
- Aura Biosciences to Present Long-Term Clinical Data for AU-011 at ASRShttps://modernod.com/news/aura-biosciences-to-present-long-term-clinical-data-for-au-011-at-asrs/2476767/Aura Biosciences announced that 2-year clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the Am
- MicroSurgical Technology Releases MST 19-Gauge Ahmed Micro Stent Cutterhttps://modernod.com/news/microsurgical-technology-releases-mst-19-gauge-ahmed-micro-stent-cutter/2476768/To address challenging microstent revision surgery, MicroSurgical Technology (MST), in collaboration with glaucoma and cataract surgeon Ike Ahmed, MD, has developed the MST 19-gauge Ahmed Micro Stent Cutter. Bringing precision and control, the new instrument enables an efficient and minimally inv
- Omeros’ Omidria Receives Product-Specific J-Code from CMShttps://modernod.com/news/omeros-omidria-receives-product-specific-j-code-from-cms/2476766/Omeros announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3%. Omidria is
- Allegro Ophthalmics to Present Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at ASRShttps://modernod.com/news/allegro-ophthalmics-to-present-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-asrs/2476765/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD) will be presented during the Americ
- Iveric bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapyhttps://modernod.com/news/iveric-bio-announces-successful-advancement-of-lca10-minigene-program-and-expansion-of-orphan-gene-therapy/2476762/Iveric bio announced that the company has exercised its option and entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize mutation independent novel adeno-associated virus (AAV) gene therapy product candidates
- Ocuphire Pharma Raises Over $5 Million to Complete Late Phase 2 Clinical Trials for Ophthalmic Disordershttps://modernod.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/Ocuphire Pharma announced that it has closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision distur
- B+L Introduces FreeFlow Infusion System and 23-Gauge Bi-Blade Dual Port Vitrectomy Cutterhttps://modernod.com/news/bausch-lomb-introduces-freeflow-infusion-system-for-retina-surgery/2476761/Bausch + Lomb announced the launch of the FreeFlow infusion system for retina surgery and the 23-gauge Bi-Blade dual port vitrectomy cutter for the Stellaris Elite vision enhancement system. The FreeFlow infusion system allows for higher level of infusion flow compared to previous generati
- Notal Vision Diagnostic Clinic Reports Completion of 6 Million ForeseeHome AMD Home-Monitoring Testshttps://modernod.com/news/notal-vision-diagnostic-clinic-reports-completion-of-6-million-foreseehome-amd-home-monitoring-tests/2476750/Notal Vision announced the completion of 6 million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD, according to a company news release. ForeseeHo
- Nidek Launches LPM Low Power Mode for YLC-500 Vixihttps://modernod.com/news/nidek-launches-lpm-low-power-mode-for-ylc-500-vixi/2476744/Nidek has announced the launch of LPM optional software, a low power mode for the YLC-500 Vixi laser photocoagulator. LPM delivers a therapeutic effect to the retina by decreasing the laser power during photocoagulati